-
Accrual to Radiotherapy Trials in the US-Pitfalls and Potential Solutions. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Nina N Sanford,William A Hall
-
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Paolo Tarantino, Gabriel Hortobagyi, Sara M. Tolaney, Elizabeth A. Mittendorf
ImportanceOver the past 2 decades, systemic therapy for early-stage breast cancer has gradually moved from the adjuvant to the neoadjuvant setting. Administration of systemic therapy before surgery leads to potential improvements in surgical outcomes and allows for the assessment of the pathologic response to treatment. For patients with residual disease (RD), 3 adjuvant strategies have been shown
-
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M. Fanaeian, Mark Knafl, Jennifer Peterson, Mohammad Zeineddine, Kristin Alfaro, Fadl Zeineddine, Drew Goldstein, Nicholas Hornstein, Arvind Dasari, Ryan Huey, Benny Johnson, Victoria Higbie, Alisha Bent, Bryan Kee, Michael Lee, Maria Pia Morelli, Van Karlyle Morris, Daniel Halperin, Michael J. Overman, Christine Parseghian, Eduardo Vilar
ImportanceDisparity in overall survival (OS) and differences in the frequency of driver gene variants by race and ethnicity have been separately observed in patients with colorectal cancer; however, how these differences contribute to survival disparity is unknown.ObjectiveTo quantify the association of molecular, socioeconomic, and clinical covariates with racial and ethnic disparities in overall
-
Cervical Cancer Incidence in the US-Affiliated Pacific Islands JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Sameer V. Gopalani, Jin Qin, Janos Baksa, Trevor D. Thompson, Mona Saraiya, Virginia Senkomago, Paran Pordell, Youngju Jeong, Neal A. Palafox, Martina Reichhardt, Lee E. Buenconsejo-Lum
ImportanceThe World Health Organization has called for eliminating cervical cancer as a public health problem. Accurate and up-to-date estimates of population-based cervical cancer incidence are essential for monitoring progress toward elimination and informing local cancer control strategies, but these estimates are lacking for the US-Affiliated Pacific Islands (USAPI).ObjectiveTo calculate age-standardized
-
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Gustav Y. Cederquist, Lillian A. Boe, Michael Walsh, Gary M. Freedman, Kara N. Maxwell, Neil Taunk, Lior Z. Braunstein
This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.
-
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-05 Catherine A. O’Connor, Emily Harrold, David Lin, Henry Walch, Andrea Gazzo, Megha Ranganathan, Sarah Kane, Fergus Keane, Joshua Schoenfeld, Drew Moss, Deborah M. Thurtle-Schmidt, Sarah P. Suehnholz, Debyani Chakravarty, Fiyinfolu Balogun, Anna Varghese, Kenneth Yu, David Kelsen, Alicia Latham, Britta Weigelt, Wungki Park, Zsofia Stadler, Eileen M. O’Reilly
ImportanceMicrosatellite (MS) instability (MSI-H) occurs frequently in Lynch syndrome (LS)–associated tumors and is associated with response to immune checkpoint blockade (ICB) therapy. MSI-H is conferred by germline or somatic variants in mismatch repair genes. The contribution of somatic oncogenesis to MSI-H in pancreatic cancer (PC) is unknown.ObjectiveTo evaluate an LS-related PC cohort to define
-
Frequency of ERBB2-Low Expression in Endometrial Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-05 Camilla Krakstad,Hege F Berg,Kristina Lindemann,Mari Kyllesø Halle
-
Persons With Cancer Rather Than Cancer Patients-Semantics Matter. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-05 Frederic Ivan L Ting
-
Inpatient Care and Outcomes Among People With Cancer Experiencing Homelessness JAMA Oncol. (IF 22.5) Pub Date : 2024-09-05 Kanan Shah, Patricia Mae G. Santos, Lillian A. Boe, Justin M. Barnes, Anna Tao, C. Jillian Tsai, Fumiko Chino
ImportanceCancer is a leading cause of death among people experiencing homelessness (PEH) in the US. Acute care settings are important sources of care for PEH; however, the association of housing status with inpatient care remains understudied, particularly in the context of cancer.ObjectiveTo assess whether housing status is associated with differences in the inpatient care of hospitalized adults
-
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-29 Xue Bai,Xia Cui,Wenquan Niu
-
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-29 Jean Feng,Isabel Friesner,Julian C Hong
-
Caring for Your Heart During Cancer Treatment JAMA Oncol. (IF 22.5) Pub Date : 2024-08-29 Manu Mysore, Dylan Singhi, Eric K. Singhi
This JAMA Oncology Patient Page describes cardio-oncology, a relatively new area in medicine that focuses on taking care of the heart while going through cancer treatments.
-
Neoadjuvant Immune Checkpoint Inhibitors Plus Chemotherapy in Early Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-08-29 Guillermo Villacampa, Victor Navarro, Alexios Matikas, Joana Mourato Ribeiro, Francesco Schettini, Pablo Tolosa, Olga Martínez-Sáez, Rodrigo Sánchez-Bayona, Juan M. Ferrero-Cafiero, Fernando Salvador, Andri Papakonstantinou, Aleix Prat, Mafalda Oliveira, Tomas Pascual
ImportanceRecent studies have investigated the combination of immune checkpoint inhibitors (ICIs) with (neo)adjuvant chemotherapy in early-stage breast cancer. However, there is an ongoing debate about the optimal approach for integrating this strategy.ObjectivesTo evaluate the association of neoadjuvant ICIs with pathologic complete response (pCR) across molecular phenotypes, to quantify the survival
-
Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers JAMA Oncol. (IF 22.5) Pub Date : 2024-08-29 Sjoerd J. F. Hermans, Niek G. van der Maas, Yvette van Norden, Avinash G. Dinmohamed, Elizabeth Berkx, Peter C. Huijgens, Donna R. Rivera, R. Angelo de Claro, Francesco Pignatti, Jurjen Versluis, Jan J. Cornelissen
ImportanceThe use of real-world data (RWD) external control arms in prospective studies is increasing. The advantages, including the immediate availability of a control population, must be balanced with the requirements of meeting evidentiary standards.ObjectiveTo address the question of whether and to what extent the methods of RWD studies compare to standard methods used in randomized clinical trials
-
Identification of Immune Checkpoint Inhibitor–Induced Diabetes JAMA Oncol. (IF 22.5) Pub Date : 2024-08-29 Karina N. Ruiz-Esteves, Kaitlyn R. Shank, Aaron J. Deutsch, Alekhya Gunturi, Natalia Chamorro-Pareja, Caitlin A. Colling, Leyre Zubiri, Katherine Perlman, Tianqi Ouyang, Alexandra-Chloé Villani, Jose C. Florez, Alexander Gusev, Kerry L. Reynolds, Karen K. Miller, Miriam S. Udler, Meghan E. Sise, Michelle Rengarajan
ImportanceImmune checkpoint inhibitors (ICIs) have revolutionized cancer care; however, accompanying immune-related adverse events (irAEs) confer substantial morbidity and occasional mortality. Life-threatening irAEs may require permanent cessation of ICI, even in patients with positive tumor response. Therefore, it is imperative to comprehensively define the spectrum of irAEs to aid individualized
-
Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-22 Hassal Lee,Neal A Palafox,Tobias Janowitz
-
An Anal Lesion in a 27-Year-Old Patient. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-22 Jérémy Baude,Hugues Mura,Alexis Lépinoy
-
Inclusion of American Indian, Alaska Native, Native Hawaiian, and Pacific Islander Patients in Clinical Trial Travel Time. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-22 Megan Y Gimmen,Alec J Calac,Kekoa Taparra
-
Immune Checkpoint Inhibitor–Induced Cardiotoxicity JAMA Oncol. (IF 22.5) Pub Date : 2024-08-22 Dorte Lisbet Nielsen, Carsten Bogh Juhl, Ole Haagen Nielsen, Inna Markovna Chen, Joerg Herrmann
ImportanceImmune checkpoint inhibitors (ICIs) improve outcomes in a wide range of cancers; however, serious adverse effects, including cardiovascular adverse effects (CVAEs), can occur.ObjectiveTo determine the incidence of CVAEs and analyze data on the management of myocarditis in patients exposed to ICIs.Data SourcesPubMed, Embase, and Cochrane Central Register of Controlled Trials from inception
-
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy JAMA Oncol. (IF 22.5) Pub Date : 2024-08-22 Catherine H. Marshall, Benjamin A. Teply, Jiayun Lu, Lia Oliveira, Hao Wang, Shifeng S. Mao, W. Kevin Kelly, Channing J. Paller, Mark C. Markowski, Samuel R. Denmeade, Serina King, Rana Sullivan, Elai Davicioni, James A. Proudfoot, Mario A. Eisenberger, Michael A. Carducci, Tamara L. Lotan, Emmanuel S. Antonarakis
ImportanceOlaparib is a poly(adenosine diphosphate–ribose) polymerase inhibitor that provides benefit in combination with hormonal therapies in patients with metastatic prostate cancer who harbor homologous recombination repair (HRR) alterations. Its efficacy in the absence of androgen deprivation therapy has not been tested.ObjectiveTo determine the activity of olaparib monotherapy among patients
-
Hidden Morbidity in Cancer Care-Mental Health in Spouses. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 Casey Crump,Weiva Sieh
-
The Role of Lazertinib in Patients With EGFR-Variant Non-Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 Haiying Cheng
-
Hypofractionated Postprostatectomy Radiotherapy-Less is Really More? JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 Nicolas Benziane-Ouaritini,Thomas Zilli,Paul Sargos
-
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 Min Hee Hong, Yoon Ji Choi, Hee Kyung Ahn, Sun Min Lim, Bhumsuk Keam, Dong-Wan Kim, Tae Min Kim, Jeonghwan Youk, Yu Jung Kim, Shinwon Hwang, Sangwoo Kim, Ju Won Kim, Hye Ryun Kim, Jin Hyoung Kang
ImportanceEGFR-variant non–small cell lung cancer (NSCLC) is associated with a high rate of central nervous system (CNS) metastases, even with treatment with first-generation or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).ObjectiveTo investigate CNS activity with lazertinib, a third-generation EGFR TKI.Design, Setting, and ParticipantsThis multicenter
-
Active Surveillance for Low-Risk Cancer—The Waiting Is the Hardest Part JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 David A. Haggstrom, Signe M. Braafladt, Paul K. J. Han
This Viewpoint describes the benefits and challenges of active surveillance as a clinical approach to monitor low-risk cancers with favorable prognoses.
-
Suicide Attempt and Suicide Death Among Spouses of Patients With Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 Qianwei Liu, Fen Yang, Krisztina D. László, Kejia Hu, Maria Feychting, Dang Wei, Katja Fall, Unnur Valdimarsdóttir, Jiong Li, Fang Fang
ImportanceLittle is known about the risk of suicidal behavior in relation to having a spouse with a cancer diagnosis.ObjectiveTo estimate the risk of suicide attempt and suicide death among spouses of patients with cancer.Design, Setting, and ParticipantsThis nationwide cohort study in Denmark collected registry-based data from 1986 through 2016. Analyses were performed from August 8, 2022, to October
-
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-08-15 Ruth M. O’Regan, Yi Zhang, Gini F. Fleming, Prudence A. Francis, Roswitha Kammler, Giuseppe Viale, Patrizia Dell’Orto, Istvan Lang, Meritxell Bellet, Herve R. Bonnefoi, Carlo Tondini, Federica Villa, Antonio Bernardo, Eva M. Ciruelos, Patrick Neven, Per Karlsson, Bettina Müller, Wolfram Jochum, Khalil Zaman, Silvana Martino, Charles E. Geyer, Katarzyna J. Jerzak, Nancy E. Davidson, Robert E. Coleman
ImportanceAdjuvant ovarian function suppression (OFS) with oral endocrine therapy improves outcomes for premenopausal patients with hormone receptor–positive (HR+) breast cancer but adds adverse effects. A genomic biomarker for selecting patients most likely to benefit from OFS-based treatment is lacking.ObjectiveTo assess the predictive and prognostic performance of the Breast Cancer Index (BCI) for
-
Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-08 Otilia Ciobanu,Yixuan He,David C Qian
-
Relapse Patterns in Early-Stage Endometrial Cancer Based on Molecular Classification. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-08 Giorgio Bogani,Francesco Raspagliesi
-
Cold Capping-A Medical Student's Perspective As A Caregiver. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-08 Fiona Evans
-
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction JAMA Oncol. (IF 22.5) Pub Date : 2024-08-08 Julia S. Wong, Hajime Uno, Angela C. Tramontano, Lauren Fisher, Catherine V. Pellegrini, Gregory A. Abel, Harold J. Burstein, Yoon S. Chun, Tari A. King, Deborah Schrag, Eric Winer, Jennifer R. Bellon, Matthew D. Cheney, Patricia Hardenbergh, Alice Ho, Kathleen C. Horst, Janice N. Kim, Kara-Lynne Leonard, Meena S. Moran, Catherine C. Park, Abram Recht, Daniel E. Soto, Ron Y. Shiloh, Susan F. Stinson
ImportancePostmastectomy radiation therapy (PMRT) improves local-regional disease control and patient survival. Hypofractionation (HF) regimens have comparable efficacy and complication rates with improved quality of life compared with conventional fractionation (CF) schedules. However, the use of HF after mastectomy in patients undergoing breast reconstruction has not been prospectively examined.ObjectiveTo
-
Contemporary Management of Acute Myeloid Leukemia JAMA Oncol. (IF 22.5) Pub Date : 2024-08-08 Sangeetha Venugopal, Mikkael A. Sekeres
ImportanceAcute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual incidence rate of AML is 4.1 per 100 000 people in the US and is higher in patients older than 65 years. Acute myeloid leukemia includes numerous subgroups with heterogeneous molecular profiles, treatment response, and prognosis
-
Sublobar Resection vs Lobectomy for High-Risk Stage I Non-Small Cell Lung Carcinoma. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Jay M Lee
-
Characterizing Lung Cancer in Li-Fraumeni Syndrome. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Jessica N Hatton,John Kucera,Kenneth P Seastedt,Kelvin César de Andrade,Sharon A Savage,Payal P Khincha,Chuong D Hoang
-
Comprehensive Risk Stratification to Guide an Optimal Preventive Strategy for Breast Radiation Dermatitis-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Avidan Uriel Neumann,Kai Joachim Borm,Claudia Traidl-Hoffmann
-
Comprehensive Risk Stratification to Guide an Optimal Preventive Strategy for Breast Radiation Dermatitis. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Henry C Y Wong,Saverio Caini,Kimberly Corbin
-
Assessing the Evidence for Circulating Tumor HPV DNA in Patients With Oropharyngeal Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Nancy Y Lee,Luc G T Morris,Maximilian Diehn
-
Advancing Precision Equity With Multicancer Detection Liquid Biopsies. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Nicholas P Semenkovich,Gautum Agarwal,Aadel A Chaudhuri
-
The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance? JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Priyadarshini Pathak,Colin D Weekes,Rachna T Shroff
-
Current Management of Desmoid Tumors: A Review. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Bernd Kasper,Elizabeth H Baldini,Sylvie Bonvalot,Dario Callegaro,Kenneth Cardona,Chiara Colombo,Nadège Corradini,Aimee M Crago,Angelo P Dei Tos,Palma Dileo,Eldad Elnekave,Joseph P Erinjeri,Fariba Navid,Jeffrey M Farma,Andrea Ferrari,Marco Fiore,Rebecca A Gladdy,Mrinal Gounder,Rick L Haas,Olga Husson,Jean-Emmanuel Kurtz,Alex J Lazar,Daniel Orbach,Nicolas Penel,Ravi Ratan,Chandrajit P Raut,Christina
Importance Desmoid tumor (DT) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Previously, surgery was the standard primary treatment modality; however, within the past decade, a paradigm shift toward less-invasive management has been introduced and an effort to harmonize the strategy among clinicians has been
-
Valid Analysis of Brain-Specific Progression-Free Survival-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Tom Wei-Wu Chen,Ming-Shen Dai,Yen-Shen Lu
-
Valid Analysis of Brain-Specific Progression-Free Survival. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Stephanie Armbruster,Ethan B Ludmir,Lee-Jen Wei
-
Radiation With Immunotherapy May Be a Double-Edged Sword-How Can We Learn From Recent Negative Clinical Trials? JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Heather M McGee,Terence M Williams,Percy Lee
-
Immunotherapy For US Patients With Metastatic Cancer at the End of Life-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Dan Kerekes,Sajid Khan
-
Immunotherapy For US Patients With Metastatic Cancer at the End of Life. JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Hirotaka Higashi,Akihiko Shimomura,Chikako Shimizu
-
MRI-Linac–Based Radiotherapy—Promising or Hype? JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Mack Roach, Stella Ling, Pamela W. Coleman
This Viewpoint discusses the value of magnetic resonance imaging with linear accelerator (MRI-linac) technology, given the unmet needs in its development.
-
Aspirin Use and Incidence of Colorectal Cancer According to Lifestyle Risk JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Daniel R. Sikavi, Kai Wang, Wenjie Ma, David A. Drew, Shuji Ogino, Edward L. Giovannucci, Yin Cao, Mingyang Song, Long H. Nguyen, Andrew T. Chan
ImportanceAspirin reduces the risk of colorectal cancer (CRC). Identifying individuals more likely to benefit from regular aspirin use for CRC prevention is a high priority.ObjectiveTo assess whether aspirin use is associated with the risk of CRC across different lifestyle risk factors.Design, Setting, and ParticipantsA prospective cohort study among women in the Nurses’ Health Study (1980-2018) and
-
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Eli Muchtar, Brendan Wisniowski, Susan Geyer, Giovanni Palladini, Paolo Milani, Giampaolo Merlini, Stefan Schönland, Kaya Veelken, Ute Hegenbart, Nelson Leung, Angela Dispenzieri, Shaji K. Kumar, Efstathios Kastritis, Meletios A. Dimopoulos, Michaela Liedtke, Patricia Ulloa, Vaishali Sanchorawala, Raphael Szalat, Katharine Dooley, Heather Landau, Erica Petrlik, Suzanne Lentzsch, Alexander Coltoff,
ImportanceKidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes.ObjectiveTo validate graded kidney response criteria and their association with kidney and overall survival (OS).Design, Setting
-
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Nasser Altorki, Xiaofei Wang, Bryce Damman, David R. Jones, Dennis Wigle, Jeffrey Port, Massimo Conti, Ahmad S. Ashrafi, Moishe Lieberman, Rodney Landreneau, Kazuhiro Yasufuku, Stephen Yang, John D. Mitchell, Robert Keenan, Thomas Bauer, Daniel Miller, David Kozono, Jennifer Mentlick, Everett Vokes, Thomas E. Stinchcombe
ImportanceThe randomized clinical trial Cancer and Leukemia Group B (CALGB) 140503 showed that for patients with clinically staged T1N0 non–small cell lung cancer (NSCLC; ≤2 cm), sublobar resections were associated with similar oncological outcomes to those after lobar resection. The association of the extent of parenchymal resection with recurrence and survival in patients with tumors pathologically
-
When Best Care Takes a Back Seat to the Bottom Line JAMA Oncol. (IF 22.5) Pub Date : 2024-08-01 Jonathan E. Leeman, Zhaohui Han, Daphne A. Haas-Kogan
This Viewpoint discusses the clinical vs economic success of magnetic resonance imaging combined with linear accelerator technology and its impact on patients.
-
Contralateral Breast Cancer Remains a Complex Biologic Conundrum. JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Seema Ahsan Khan,Masha Kocherginsky
-
Population-Based Incidence of Cervical Intraepithelial Neoplasia Across 14 Years of HPV Vaccination JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Rachael Adcock, Huining Kang, Philip E. Castle, Walter Kinney, Rebecca T. Emeny, Charles Wiggins, Cosette M. Wheeler
This cohort study examines the incidence of cervical intraepithelial neoplasia during a period of increasing human papillomavirus (HPV) vaccination coverage from 2007 to 2020.
-
Bilateral Mastectomy and Breast Cancer Mortality JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Vasily Giannakeas, David W. Lim, Steven A. Narod
ImportanceThe benefit of bilateral mastectomy for women with unilateral breast cancer in terms of deaths from breast cancer has not been shown.ObjectivesTo estimate the 20-year cumulative risk of breast cancer mortality among women with stage 0 to stage III unilateral breast cancer according to the type of initial surgery performed.Design, Settings, and ParticipantsThis cohort study used the Surveillance
-
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Wanting Qiang, Jing Lu, Yanchun Jia, Jia Liu, Jin Liu, Haiyan He, Xiaoxiang Wang, Xiaoqiang Fan, Lina Jin, Qianqi Ruan, Qi Zhang, Lianjun Shen, Lihong Weng, Wei Cao, Wenling Li, Juan Du
ImportancePatients with high-risk newly diagnosed multiple myeloma (NDMM) often have poor outcomes with standard treatments, necessitating novel effective frontline therapies to enhance clinical outcomes. GC012F, a B-cell maturation antigen/CD19 dual-targeting chimeric antigen receptor (CAR) T-cell therapy, has been developed on the novel FasTCAR platform. Notably, its use as a frontline therapy for
-
Hormone Deprivation–Free Survival—Inequities Persist in Research Priorities for Patients With Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Benjamin Hopkins, Reshma Jagsi, Mylin Torres
This Viewpoint discusses the importance of hormone deprivation–free survival as an end point for both men with prostate cancer and women with breast cancer.
-
Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Michael Birrer, Guiling Li, Mayu Yunokawa, Jung-Yun Lee, Byoung Gie Kim, Christina Pimentel Oppermann, Qi Zhou, Shin Nishio, Aikou Okamoto, Xiaohua Wu, Linda Mileshkin, Ana Oaknin, Isabelle Ray-Coquard, Kosei Hasegawa, Genevieve Jehl, Yulia Vugmeyster, Sen Zhang, Marcis Bajars, Kan Yonemori
ImportanceCervical cancer is a common and lethal cancer worldwide. Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (or transforming growth factor β trap) fused via a flexible linker to the C-terminus of each heavy chain of an immunoglobulin G1 antibody blocking programmed cell death 1 ligand 1
-
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Heather H. Cheng, Jeffrey W. Shevach, Elena Castro, Fergus J. Couch, Susan M. Domchek, Rosalind A. Eeles, Veda N. Giri, Michael J. Hall, Mary-Claire King, Daniel W. Lin, Stacy Loeb, Todd M. Morgan, Kenneth Offit, Colin C. Pritchard, Edward M. Schaeffer, Brittany M. Szymaniak, Jason L. Vassy, Bryson W. Katona, Kara N. Maxwell
ImportanceHalf of all carriers of inherited cancer-predisposing variants in BRCA1 and BRCA2 are male, but the implications for their health are underrecognized compared to female individuals. Germline variants in BRCA1 and BRCA2 (also known as pathogenic or likely pathogenic variants, referred to here as BRCA1/2 PVs) are well known to significantly increase the risk of breast and ovarian cancers in
-
Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non–Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-07-25 Helen J. Ross, David Kozono, Xiaofei F. Wang, James John Urbanic, Terence M. Williams, Garth D. Nelson, David P. Carbone, Dongjun Chung, Ryan Robb, Woo Yul Byun, Tiffany Talabere, Carter DuFrane, Ilze Bara, Katja Schulze, Michelle Brockman, Junheng Gao, Everett E. Vokes, Thomas E. Stinchcombe
ImportanceOutcomes for patients with unresectable stage III non–small cell lung cancer (NSCLC) treated with chemoradiation therapy (CRT) have improved with adjuvant immune checkpoint inhibitors, with a reported 5-year overall survival benefit of approximately 10% for adjuvant durvalumab vs placebo after completion of CRT without progression and with preserved performance status. Starting atezolizumab
-
Exercise for Prostate Cancer-Worthy Goals but Suboptimal Trial Designs. JAMA Oncol. (IF 22.5) Pub Date : 2024-07-18 Marian L Neuhouser,Jeannette M Schenk,Jonathan L Wright
-
Neoadjuvant Exercise Therapy in Prostate Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-07-18 Lee W. Jones, Chaya S. Moskowitz, Catherine P. Lee, Gina A. Fickera, Su S. Chun, Meghan G. Michalski, Kurtis Stoeckel, Whitney P. Underwood, Jessica A. Lavery, Umeshkumar Bhanot, Irina Linkov, Chau T. Dang, Behfar Ehdaie, Vincent P. Laudone, James A. Eastham, Anne Collins, Patricia T. Sheerin, Lydia Y. Liu, Stefan E. Eng, Paul C. Boutros
ImportanceObservational data have shown that postdiagnosis exercise is associated with reduced risk of prostate cancer death. The feasibility and tumor biological activity of exercise therapy is not known.ObjectiveTo identify recommended phase 2 dose of exercise therapy for patients with prostate cancer.Design, Setting, and ParticipantsThis single-center, phase 1a dose-finding trial was conducted at